Treatment Strategies and Challenges in the Co-Management of Type 2 Diabetes and Tuberculosis


double epidemic
treatment strategies
type 2 diabetes mellitus

How to Cite

Vishwanath Ingle, P., Sivanandy, P., Tse Yee, W. ., Siaw Ying, W. ., Kai Heng, T. ., Hang Chong, T. ., Zhi Xiang, T., Lean Tsu Ching, W. ., & Kit Mun, T. . (2022). Treatment Strategies and Challenges in the Co-Management of Type 2 Diabetes and Tuberculosis. Journal of Pharmacy and Nutrition Sciences, 12, 1–10.


Despite rapid advances in the healthcare field, diabetes mellitus (DM) and tuberculosis (TB) continues to be a global burden that affects millions of people every year. The association between DM and TB has been known for an extended period. The last 15 years, however, have seen an increased number of studies showing that diabetes (both type 1 and type 2) increases the risk of tuberculosis because of impaired immune defences and likewise, TB may induce hyperglycemia and therefore increase the risk of DM. When DM and TB co-exist as dual diseases, it complicates management strategies as treatment outcomes are affected. In developing countries where the epidemic of DM and TB is rapidly growing, the presence of a concomitant disease becomes a challenge to the affected nation and could also impact DM and TB control on a global scale. This review brings together information on what is currently known about T2DM and TB as a double epidemic, the recommended treatment strategies, and the challenges involved in disease management. Furthermore, we address the future perspectives of the co-management of T2DM and TB and what can be done to overcome the shortcomings of currently available guidelines.


International Diabetes Federation - Home [Internet]. [cited 2019 Mar 4]. Available from:

Lin Y, Harries A D, Kumar A M V, Critchley J A, van Crevel R, Owiti P, Dlodlo R A, Dejgaard A. Management of diabetes mellitus-tuberculosis: a guide to the essential practice. Paris, France: International Union Against Tuberculosis and Lung Disease, 2018.

Global tuberculosis report 2018. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO.

Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. The Lancet Infectious Diseases 2009 12; 9(12): 737-46.

Geerlings S, Hoepelman A. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunology & Medical Microbiology 1999; 26(3-4): 259-265.

Agarwal A, Ginisha G, Preeti G, Dwivedi S, Swamai P. The association between diabetes and tuberculosis may be the next challenge for global tuberculosis control worldwide. Indian Journal of Endocrinology and Metabolism 2016; 20(5): 732.

Singh S, Singh S, Kishan J, Kaur S, Ramana S. Association of tuberculosis and Diabetes Mellitus: an analysis of 1000 consecutively admitted cases in a tertiary care hospital of North India. Pan African Medical Journal 2016; 24.

Dobler C, Flack J, Marks G. Risk of tuberculosis among people with diabetes mellitus: an Australian nationwide cohort study 2019.

ReyPineda G D. Type 2 Diabetes Mellitus as a Risk Factor for Tuberculosis. Mycobacterial Diseases 2014; 04(02).

Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab 2012; 16(Suppl 1): S27-36.

Peleg AY, Weerarathna T, McCarthy JS, Davis TME. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes-Metabolism Research and Reviews 2007; 23(1): 3-13.

Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N Engl J Med 1999; 341(25): 1906-12.

Restrepo BI, Camerlin AJ, Rahbar MH, Wang WW, Restrepo MA, Zarate I, et al. Cross-sectional assessment reveals high diabetes prevalence among newly-diagnosed tuberculosis cases. Bulletin of the World Health Organization 2011; 89(5): 352-9.

Skowroński M, Zozulińska-Ziółkiewicz D, Barinow-Wojewódzki A. State of the art paper Tuberculosis and diabetes mellitus - an underappreciated association. Archives of Medical Science 2014; 5: 1019-1027.

Jiménez-Corona M, Cruz-Hervert L, García-García L, Ferreyra-Reyes L, Delgado-Sánchez G, Bobadilla-del-Valle M et al. Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes 2012.

Rayfield EJ, Ault MJ, Keusch GT, Brothers MJ, Nechemias C, Smith H. Infection and diabetes: the case for glucose control. Am J Med 1982; 72(3): 439-50.

Yamashiro S, Kawakami K, Uezu K, Kinjo T, Miyagi K, Nakamura K, Saito A. Lower expression of Th1-related cytokines and inducible nitric oxide synthase in mice with streptozotocin-induced diabetes mellitus infected with Mycobacterium tuberculosis. Clin Exp Immunol 2005; 139: 57-64.

Martens GW, Arikan MC, Lee J, Ren F, Greiner D, Kornfeld H. Tuberculosis susceptibility of diabetic mice. Am J Respir Cell Mol Biol 2007; 37: 518-524.

Restrepo BI, Fisher-Hoch SP, Pino PA, Salinas A, Rahbar MH, Mora F, Cortes-Penfield N, McCormick JB. Tuberculosis in poorly controlled type 2 diabetes: altered cytokine expression in peripheral white blood cells. Clin Infect Dis 2008; 47: 634-641.

Restrepo B. Diabetes and Tuberculosis. Tuberculosis and Nontuberculous Mycobacterial Infections, Seventh Edition: 595-606.

Kumar NP, Sridhar R, Banurekha VV, Jawahar MS, Nutman TB, et al. Expansion of pathogen-specific T-helper 1 and T-helper 17 cells in pulmonary tuberculosis withcoincidenttype 2 diabetes mellitus. J Infect Dis 2013; 208: 739-748.

Viardot A, Grey ST, Mackay F, Chisholm D. Potential antiinflammatory role of insulin via the preferential polarization of effector T cells toward a T helper 2 phenotype. Endocrinology 2007; 148(1): 346-53.

van Exel E, Gussekloo J, de Craen AJ, et al. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes : the Leiden 85-Plus study. Diabetes 2002; 51: 1088-92.

Tsukaguchi K, Okamura H, Matsuzawa K, et al. (Longitudinal assessment of IFN-gamma production in patients with pulmonary tuberculosis complicated with diabetes mellitus). Kekkaku: (Tuberculosis) 2002; 77: 409-13.

Tsukaguchi K, Yoneda T, Yoshikawa M, et al. (Case study of interleukin-1 beta, tumor necrosis factor alpha and interleukin-6 production peripheral blood monocytes in patients with diabetes mellitus complicated by pulmonary tuberculosis). Kekkaku: (Tuberculosis) 1992; 67: 755-60.

Wang CH, Yu CT, Lin HC, et al. Hypodense alveolar macrophages in patients with diabetes mellitus and active pulmonary tuberculosis. Tuberc Lung Dis 1999; 79: 235-42.

Moutschen MP, Scheen AJ, Lefebvre PJ. Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabete Metab 1992; 18: 187-201

Vallerskog T, Martens G, Kornfeld H. Diabetic mice display adaptive immune response to Mycobacterium tuberculosis. J Immunol 2010; 184: 6275-82.

Yorke E, Atiase Y, Akpalu J, Sarfo-Kantanka O, Boima V, Dey I. The Bidirectional Relationship between Tuberculosis and Diabetes. Tuberculosis Research and Treatment 2017; 2017: 1-6.

Niazi A, Kalra S. Diabetes and tuberculosis: a review of the role of optimal glycemic control. Journal of Diabetes & Metabolic Disorders 2012; 11(1): 28.

Guptan A, Shah A. Tuberculosis and diabetes: an appraisal. Indian Journal of Tuberculosis 2000; 47(3): 2-8.

Wang J, Lee M, Shu C, Lee C, Lee L, Chao K, et al. Optimal Duration of Anti-TB Treatment in Patients With Diabetes: Nine or Six Months? Chest Invalid date 147(2): 520-528.

Stott KE, Pertinez H, Sturkenboom MGG, Boeree MJ, Aarnoutse R, Ramachandran G, et al. Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. J Antimicrob Chemother Invalid date 73(9): 2305-2313.

Plemper van Balen G, van Ingen J, Boeree MJ, Aarnoutse RE, Donald PR, Diacon AH, et al. Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment? CID 2011; 52(9): e194-e199.

van Crevel R, Koesoemadinata R, Hill PC, Harries AD. Clinical management of combined tuberculosis and diabetes. The International Journal of Tuberculosis and Lung Disease 2018; 22(12): 1404-1410.

Beran D, Ewen M, Laing R. Constraints and challenges in access to insulin: a global perspective. Lancet Diabetes Endocrinol 2016; 4(3): 275-285.

Treatment of Tuberculosis: Guidelines. 4th ed. Geneva: World Health Organization; 2010.

Al-Shaer M, Mansour H, Elewa H, Salameh P, Iqbal F. Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar. BMC Infectious Diseases 2017; 17(1): 118; 118-118.

Riza AL, Pearson F, Ugarte-Gil C, Alisjahbana B, van de Vijver S, Panduru NM, et al. Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinol 2014; 2(9): 740-53.

Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15(6): 540-59.

Sun H, Scott DO. Impact of genetic polymorphisms of cytochrome P450 2 C (CYP2C) enzymes on the drug metabolism and design of antidiabetics. Chemico-Biological Interactions 2011; 194(2): 159-167.

Degner NR, Wang J-Y, Golub JE, Karakousis PC. Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment. Clin Infect Dis 2018; 66(2): 198-205.

Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in Patients With Type 2 Diabetes and Kidney Disease. JAMA 2014; 312(24): 2668-75.

Drive ADA 2451 C, Arlington S 900, Va 22202 1-800-Diabetes. A1C and eAG [Internet]. American Diabetes Association. [cited 2019 Mar 9]. Available from:

Vitamin D status in tuberculosis patients with diabetes, prediabetes and normal blood glucose in China: a cross-sectional study. BMJ Open [Internet] 2017 [cited 21 February 2019]; Available from:

Vitamin D and Tuberculosis Patients [Internet]. 2018 [cited 21 February 2019]. Available from:

Martin T, Campbell R. Vitamin D and Diabetes [Internet] 2011 [cited 21 February 2019].

Kota S, Jammula S, Kota S, Tripathy P, Panda S, Modi K. Effect of vitamin D supplementation in type 2 diabetes patients with pulmonary tuberculosis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews [Internet] 2011 [cited 21 February 2019]; 5(2): 85-89.

Nursyam EW, Amin Z, Rumende CM. The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta Med Indones 2006; 38: 3-5.

Baker MA, Harries AD, Jeon CY, Hart JE, Kapur A, Lönnroth K, et al. The impact of diabetes on tuberculosis treatment outcomes: A systematic review. BMC Medicine 2011; 9(1): 81.

Stalenhoef JE, Alisjahbana B, Nelwan EJ, van der Ven-Jongekrijg J, Ottenhoff THM, van der Meer JWM, et al. The role of interferon-gamma in the increased tuberculosis risk in type 2 diabetes mellitus. Eur J Clin Microbiol Infect Dis 2008; 27(2): 97-103.

Al‐Attiyah RJ, Mustafa AS. Mycobacterial antigen-induced T helper type 1 (Th1) and Th2 reactivity of peripheral blood mononuclear cells from diabetic and non-diabetic tuberculosis patients and Mycobacterium bovis bacilli Calmette-Guérin (BCG)-vaccinated healthy subjects. Clinical & Experimental Immunology 2009; 158(1): 64-73.

Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic Interactions with Rifampicin. Clin Pharmacokinet 2003; 42(9): 819-50.

Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivistö KT. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther 2001; 69(6): 400-6.

Niemi M, Backman JT, Neuvonen PJ. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin Pharmacol Ther 2004; 76(3): 239-49.

Park J-Y, Kim K-A, Kang M-H, Kim S-L, Shin J-G. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther 2004; 75(3): 157-62.

Jaakkola T, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ. Effect of rifampicin on the pharmacokinetics of pioglitazone. British Journal of Clinical Pharmacology 2006; 61(1): 70-8.

Hall RG, Leff RD, Gumbo T. Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2009; 29(12): 1468-81.

Sullivan T, Amor YB. The Co-Management of Tuberculosis and Diabetes: Challenges and Opportunities in the Developing World. PLOS Medicine 2012; 9(7): e1001269.

Grant P. Management of diabetes in resource-poor settings. Clin Med 2013; 13(1): 27-31.

Harries AD, Jahn A, Zachariah R, Enarson D. Adapting the DOTS Framework for Tuberculosis Control to the Management of Non-Communicable Diseases in Sub-Saharan Africa. PLOS Medicine 2008; 5(6): e124.

Mahishale V, Avuthu S, Patil B, Lolly M, Eti A, Khan S. Effect of Poor Glycemic Control in Newly Diagnosed Patients with Smear-Positive Pulmonary Tuberculosis and Type-2 Diabetes Mellitus. Iran J Med Sci 2017; 42(2): 144-51.

Magee MJ, Bloss E, Shin SS, Contreras C, Huaman HA, Ticona JC, et al. Clinical characteristics, drug resistance, and treatment outcomes among tuberculosis patients with diabetes in Peru. Int J Infect Dis 2013; 17(6): e404-412.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright (c) 2022 Pravinkumar Vishwanath Ingle, Palanisamy Sivanandy, Wong Tse Yee, Wong Siaw Ying, Tee Kai Heng, Tang Hang Chong, Tan Zhi Xiang, Wendy Lean Tsu Ching, Toh Kit Mun